Search

Your search keyword '"Brouwer, Jorn"' showing total 38 results
Start Over Author "Brouwer, Jorn"
38 results on '"Brouwer, Jorn"'

1. Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves

Author

Pagnesi, Matteo, Kim, Won-Keun, Baggio, Sara, Scotti, Andrea, Barbanti, Marco, De Marco, Federico, Adamo, Marianna, Eitan, Amnon, Estévez-Loureiro, Rodrigo, Conradi, Lenard, Toggweiler, Stefan, Mylotte, Darren, Veulemans, Verena, Søndergaard, Lars, Wolf, Alexander, Giannini, Francesco, Maffeo, Diego, Pilgrim, Thomas, Montorfano, Matteo, Zweiker, David, Ferlini, Marco, Kornowski, Ran, Hildick-Smith, David, Taramasso, Maurizio, Abizaid, Alexandre, Schofer, Joachim, Sinning, Jan-Malte, Van Mieghem, Nicolas M., Wöhrle, Jochen, Khogali, Saib, Van der Heyden, Jan A.S., Wood, David A., Ielasi, Alfonso, MacCarthy, Philip, Brugaletta, Salvatore, Hamm, Christian W., Costa, Giuliano, Testa, Luca, Massussi, Mauro, Alarcón, Robert, Schäfer, Ulrich, Brunner, Stephanie, Reimers, Bernhard, Lunardi, Mattia, Zeus, Tobias, Vanhaverbeke, Maarten, Naber, Christoph K., Di Ienno, Luca, Buono, Andrea, Windecker, Stephan, Schmidt, Albrecht, Lanzillo, Giuseppe, Vaknin-Assa, Hana, Arunothayaraj, Sandeep, Saccocci, Matteo, Siqueira, Dimytri, Brinkmann, Christina, Sedaghat, Alexander, Ziviello, Francesca, Seeger, Julia, Rottbauer, Wolfgang, Brouwer, Jorn, Buysschaert, Ian, Jelisejevas, Julius, Bharucha, Apurva, Regueiro, Ander, Metra, Marco, Colombo, Antonio, Latib, Azeem, and Mangieri, Antonio

Published
2023
Full Text
View/download PDF

4. Unplanned Percutaneous Coronary Revascularization After TAVR: A Multicenter International Registry

Author

Stefanini, Giulio G., Cerrato, Enrico, Pivato, Carlo Andrea, Joner, Michael, Testa, Luca, Rheude, Tobias, Pilgrim, Thomas, Pavani, Marco, Brouwer, Jorn, Lopez Otero, Diego, Munoz Garcia, Erika, Barbanti, Marco, Biasco, Luigi, Varbella, Ferdinando, Reimers, Bernhard, Jimenez Diaz, Victor Alfonso, Leoncini, Massimo, Salido Tahoces, Maria Luisa, Ielasi, Alfonso, de la Torre Hernandez, Jose M., Mylotte, Darren, Garot, Philippe, Chieffo, Alaide, and Nombela-Franco, Luis

Published
2021
Full Text
View/download PDF

9. Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry)

Author

Pagnesi, Matteo, Kim, Won-Keun, Conradi, Lenard, Barbanti, Marco, Stefanini, Giulio G., Schofer, Joachim, Hildick-Smith, David, Pilgrim, Thomas, Abizaid, Alexandre, Zweiker, David, Testa, Luca, Taramasso, Maurizio, Wolf, Alexander, Webb, John G., Sedaghat, Alexander, Van der Heyden, Jan A.S., Ziviello, Francesca, MacCarthy, Philip, Hamm, Christian W., Bhadra, Oliver D., Schäfer, Ulrich, Costa, Giuliano, Tamburino, Corrado, Cannata, Francesco, Reimers, Bernhard, Eitan, Amnon, Alsanjari, Osama, Asami, Masahiko, Windecker, Stephan, Siqueira, Dimytri, Schmidt, Albrecht, Bianchi, Giovanni, Bedogni, Francesco, Saccocci, Matteo, Maisano, Francesco, Jensen, Christoph J., Naber, Christoph K., Alenezi, Abdullah, Wood, David A., Sinning, Jan-Malte, Brouwer, Jorn, Tzalamouras, Vasileios, Van Mieghem, Nicolas M., Colombo, Antonio, and Latib, Azeem

Published
2020
Full Text
View/download PDF

10. Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial

Author

van Ginkel, Dirk Jan, primary, Bor, Willem L., additional, Dubois, Christophe L.F., additional, Aarts, Hugo M., additional, Rooijakkers, Maxim J.P., additional, van Bergeijk, Kees H., additional, Rosseel, Liesbeth, additional, Veenstra, Leo, additional, De Backer, Ole, additional, Van Mieghem, Nicolas M., additional, van der Kley, Frank, additional, Wilgenhof, Adriaan, additional, Leonora, Remigio, additional, Halim, Jonathan, additional, Schotborgh, Carl E., additional, Barbato, Emanuele, additional, Van Der Heyden, Jan A.S., additional, Frambach, Peter, additional, Ferdinande, Bert, additional, Mylotte, Darren, additional, Fabris, Enrico, additional, Rensing, Benno J.W.M., additional, Timmers, Leo, additional, Swaans, Martin J., additional, Brouwer, Jorn, additional, Nijenhuis, Vincent J., additional, Peper, Joyce, additional, Vriesendorp, Pieter A., additional, de Laat, Bas, additional, Ninivaggi, Marisa, additional, Stragier, Hendrik, additional, Voskuil, Michiel, additional, IJsselmuiden, Alexander J.J., additional, Hermanides, Renicus S., additional, Agostoni, Pierfrancesco, additional, van 't Hof, Arnoud W.J., additional, Wykrzykowska, Joanna J., additional, van Royen, Niels, additional, Delewi, Ronak, additional, and ten Berg, Jurrien M., additional

Published
2023
Full Text
View/download PDF

14. Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves

Author

Pagnesi, Matteo, Kim, Won-Keun, Conradi, Lenard, Barbanti, Marco, Stefanini, Giulio G., Zeus, Tobias, Pilgrim, Thomas, Schofer, Joachim, Zweiker, David, Testa, Luca, Taramasso, Maurizio, Hildick-Smith, David, Abizaid, Alexandre, Wolf, Alexander, Van Mieghem, Nicolas M., Sedaghat, Alexander, Wöhrle, Jochen, Khogali, Saib, Van der Heyden, Jan A.S., Webb, John G., Estévez-Loureiro, Rodrigo, Mylotte, Darren, MacCarthy, Philip, Brugaletta, Salvatore, Hamm, Christian W., Bhadra, Oliver D., Schäfer, Ulrich, Costa, Giuliano, Tamburino, Corrado, Cannata, Francesco, Reimers, Bernhard, Veulemans, Verena, Asami, Masahiko, Windecker, Stephan, Eitan, Amnon, Schmidt, Albrecht, Bianchi, Giovanni, Bedogni, Francesco, Saccocci, Matteo, Maisano, Francesco, Alsanjari, Osama, Siqueira, Dimytri, Jensen, Christoph J., Naber, Christoph K., Ziviello, Francesca, Sinning, Jan-Malte, Seeger, Julia, Rottbauer, Wolfgang, Brouwer, Jorn, Alenezi, Abdullah, Wood, David A., Tzalamouras, Vasileios, Regueiro, Ander, Colombo, Antonio, and Latib, Azeem

Published
2019
Full Text
View/download PDF

16. Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries

Author

Scotti, Andrea, Baggio, Sara, Pagnesi, Matteo, Barbanti, Marco, Adamo, Marianna, Eitan, Amnon, Estévez-Loureiro, Rodrigo, Veulemans, Verena, Toggweiler, Stefan, Mylotte, Darren, De Marco, Federico, Giannini, Francesco, Ferlini, Marco, Naber, Christoph K, Buono, Andrea, Schofer, Joachim, Rottbauer, Wolfgang, Van Mieghem, Nicolas M, Khogali, Saib, Taramasso, Maurizio, Pilgrim, Thomas, Sinning, Jan-Malte, Zweiker, David, Montorfano, Matteo, Van der Heyden, Jan A S, Brugaletta, Salvatore, Ielasi, Alfonso, Hamm, Christian W, Vanhaverbeke, Maarten, Costa, Giuliano, Massussi, Mauro, Alarcón, Robert, Zeus, Tobias, Lunardi, Mattia, Testa, Luca, Di Ienno, Luca, Lanzillo, Giuseppe, Wolf, Alexander, Maffeo, Diego, Ziviello, Francesca, Saccocci, Matteo, Windecker, Stephan, Sedaghat, Alexander, Schmidt, Albrecht, Brouwer, Jorn, Regueiro, Ander, Reimers, Bernhard, Kim, Won-Keun, Sondergaard, Lars, Colombo, Antonio, Mangieri, Antonio, and Latib, Azeem

Subjects
610 Medizin und Gesundheit
Abstract

BACKGROUND In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. METHODS This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. RESULTS In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1-4, 4.1% [2.8-6.3%], 3.7% [2.6-5.3%], 3.3% [2.4-4.9%], 2.9% [2.2-4.3%]; P

Published
2023
Full Text
View/download PDF

18. Diagnostic Performance of CCTA and CT-FFR for the Detection of CAD in TAVR Work-Up

Author

Peper, Joyce, primary, Becker, Leonie M., additional, van den Berg, Hans, additional, Bor, Willem L., additional, Brouwer, Jorn, additional, Nijenhuis, Vincent J., additional, van Ginkel, Dirk-Jan, additional, Rensing, Benno J.M.W., additional, ten Berg, Jurrien M., additional, Timmers, Leo, additional, Leiner, Tim, additional, and Swaans, Martin J., additional

Published
2022
Full Text
View/download PDF

23. The effect of transcatheter aortic valve implantation approaches on mortality

Author

Nijenhuis, Vincent J., primary, Meyer, Alexander, additional, Brouwer, Jorn, additional, Mahmoodi, Bakhtawar K., additional, Unbehaun, Axel, additional, Spaziano, Marco, additional, Buzzatti, Nicola, additional, Stundl, Anja, additional, Jørgensen, Troels H., additional, Kooistra, Nynke H.M., additional, Adamo, Marianna, additional, Saraf, Smriti, additional, Amrane, Hafid, additional, Bruschi, Giuseppe, additional, Zivelonghi, Carlo, additional, Swaans, Martin J., additional, Werner, Nikos, additional, Nickenig, Georg, additional, Hildick‐Smith, David, additional, Stella, Pieter R., additional, Latib, Azeem, additional, Soendergaard, Lars, additional, Sinning, Jan‐Malte, additional, Lefevre, Thierry, additional, Pasic, Miralem, additional, Kempfert, Jorg, additional, and Berg, Jurrien M., additional

Published
2021
Full Text
View/download PDF

26. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

Author

Brouwer, Jorn, primary, Nijenhuis, Vincent J., additional, Delewi, Ronak, additional, Hermanides, Renicus S., additional, Holvoet, Wouter, additional, Dubois, Christophe L.F., additional, Frambach, Peter, additional, De Bruyne, Bernard, additional, van Houwelingen, Gert K., additional, Van Der Heyden, Jan A.S., additional, Toušek, Petr, additional, van der Kley, Frank, additional, Buysschaert, Ian, additional, Schotborgh, Carl E., additional, Ferdinande, Bert, additional, van der Harst, Pim, additional, Roosen, John, additional, Peper, Joyce, additional, Thielen, Frederick W.F., additional, Veenstra, Leo, additional, Chan Pin Yin, Dean R.P.P., additional, Swaans, Martin J., additional, Rensing, Benno J.W.M., additional, van ’t Hof, Arnoud W.J., additional, Timmers, Leo, additional, Kelder, Johannes C., additional, Stella, Pieter R., additional, Baan, Jan, additional, and ten Berg, Jurriën M., additional

Published
2020
Full Text
View/download PDF

28. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

Author

Nijenhuis, Vincent J., primary, Brouwer, Jorn, additional, Delewi, Ronak, additional, Hermanides, Renicus S., additional, Holvoet, Wouter, additional, Dubois, Christophe L.F., additional, Frambach, Peter, additional, De Bruyne, Bernard, additional, van Houwelingen, Gert K., additional, Van Der Heyden, Jan A.S., additional, Toušek, Petr, additional, van der Kley, Frank, additional, Buysschaert, Ian, additional, Schotborgh, Carl E., additional, Ferdinande, Bert, additional, van der Harst, Pim, additional, Roosen, John, additional, Peper, Joyce, additional, Thielen, Frederick W.F., additional, Veenstra, Leo, additional, Chan Pin Yin, Dean R.P.P., additional, Swaans, Martin J., additional, Rensing, Benno J.W.M., additional, van ’t Hof, Arnoud W.J., additional, Timmers, Leo, additional, Kelder, Johannes C., additional, Stella, Pieter R., additional, Baan, Jan, additional, and ten Berg, Jurriën M., additional

Published
2020
Full Text
View/download PDF

37. Continuation versus Interruption of Oral Anticoagulation during TAVI.

Author

van Ginkel DJ, Bor WL, Aarts HM, Dubois C, De Backer O, Rooijakkers MJP, Rosseel L, Veenstra L, van der Kley F, van Bergeijk KH, Van Mieghem NM, Agostoni P, Voskuil M, Schotborgh CE, IJsselmuiden AJJ, Van Der Heyden JAS, Hermanides RS, Barbato E, Mylotte D, Fabris E, Frambach P, Dujardin K, Ferdinande B, Peper J, Rensing BJWM, Timmers L, Swaans MJ, Brouwer J, Nijenhuis VJ, Overduin DC, Adriaenssens T, Kobari Y, Vriesendorp PA, Montero-Cabezas JM, El Jattari H, Halim J, Van den Branden BJL, Leonora R, Vanderheyden M, Lauterbach M, Wykrzykowska JJ, van 't Hof AWJ, van Royen N, Tijssen JGP, Delewi R, and Ten Berg JM

Abstract

Background: One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism., Methods: We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients were randomly assigned in a 1:1 ratio to periprocedural continuation or interruption of oral anticoagulation. The primary outcome was a composite of death from cardiovascular causes, stroke from any cause, myocardial infarction, major vascular complications, or major bleeding within 30 days after TAVI., Results: A total of 858 patients were included in the modified intention-to-treat population: 431 were assigned to continuation and 427 to interruption of oral anticoagulation. A primary-outcome event occurred in 71 patients (16.5%) in the continuation group and in 63 (14.8%) in the interruption group (risk difference, 1.7 percentage points; 95% confidence interval [CI], -3.1 to 6.6; P = 0.18 for noninferiority). Thromboembolic events occurred in 38 patients (8.8%) in the continuation group and in 35 (8.2%) in the interruption group (risk difference, 0.6 percentage points; 95% CI, -3.1 to 4.4). Bleeding occurred in 134 patients (31.1%) in the continuation group and in 91 (21.3%) in the interruption group (risk difference, 9.8 percentage points; 95% CI, 3.9 to 15.6)., Conclusions: In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

38. Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries.

Author

Scotti A, Baggio S, Pagnesi M, Barbanti M, Adamo M, Eitan A, Estévez-Loureiro R, Veulemans V, Toggweiler S, Mylotte D, De Marco F, Giannini F, Ferlini M, Naber CK, Buono A, Schofer J, Rottbauer W, Van Mieghem NM, Khogali S, Taramasso M, Pilgrim T, Sinning JM, Zweiker D, Montorfano M, Van der Heyden JAS, Brugaletta S, Ielasi A, Hamm CW, Vanhaverbeke M, Costa G, Massussi M, Alarcón R, Zeus T, Lunardi M, Testa L, Di Ienno L, Lanzillo G, Wolf A, Maffeo D, Ziviello F, Saccocci M, Windecker S, Sedaghat A, Schmidt A, Brouwer J, Regueiro A, Reimers B, Kim WK, Sondergaard L, Colombo A, Mangieri A, and Latib A

Subjects
Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Time Factors, Treatment Outcome, Registries, Prosthesis Design, Risk Factors, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis
Abstract

Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves., Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated., Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1-4, 4.1% [2.8-6.3%], 3.7% [2.6-5.3%], 3.3% [2.4-4.9%], 2.9% [2.2-4.3%]; P <0.001) and more moderate or heavy valve calcification (Q1-4, 80%, 80%, 82%, 88%; P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1-4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1-4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P <0.001), with fewer permanent pacemaker implantations (Q1-4: 15.3%, 20.0%, 12.1%, 11.6%; Cochran-Armitage P =0.023) and residual mild or greater paravalvular leaks (Q1-4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001)., Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results